KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
KORU Medical Systems Receives FDA 510 Clearance for Delivery of RYSTIGGO® , Expanding Label for FreedomEDGE® Infusion System
KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow
KORU Medical Systems Announces 510 Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic
KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025
KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems
ForCast Orthopedics and KORU Medical Systems Announce Agreement for Novel Antibiotic Infusion Therapy
Cygnus intends to advance resource evaluation and technical studies following successful A$25m placement
